lundi 18 février 2019

Onco Actu du 18 février 2019


2.5 ETIOLOGIE - GÈNES



Genetic variations in a fourth gene linked to elevated leukemia risk in Hispanic children [St. Jude Children's Research Hospital]











2.6 ETIOLOGIE - ENVIRONNEMENT



France suggests glyphosate exit could be even slower than planned [Reuters]











A New Analysis Claims To Show Evidence Linking Glyphosate Exposure To A Rare Cancer [Forbes]










3.1 PRÉVENTION - TABAC



ASCO Weighs-In on Widespread Youth Tobacco Use; See the Latest National Youth Tobacco Survey Results [ASCO in Action]











Smoking may limit body’s ability to fight dangerous form of skin cancer [Cancer Research UK]











Researchers find genetic vulnerability to menthol cigarette use [NIH]











3.1.1 PRÉVENTION - TABAC - E-CIGS



We ignored the evidence linking cigarettes to cancer. Let's not do that with vaping [The Guardian]











5.10 TRAITEMENTS - ESSAIS



Major medical journals don’t follow their own rules for reporting results from clinical trials [Science]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



CMS unveils CAR-T proposal, with emphasis on patient outcomes [Biopharma Dive]











U.S. Medicare plans to track CAR-T cancer therapy outcomes [Reuters]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Small cell lung cancer may respond to combination of immunotherapy and DNA damage repair inhibitors [MD Anderson Cancer Center]











5.2 PHARMA



Bayer Snaps Up Rights to Two Cancer Drugs from Lilly’s $8B Loxo Deal [Xconomy]











As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi [Biopharma Dive]











Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) [Bayer]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Lilly Completes Acquisition of Loxo Oncology [Lilly]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Role of big data for evaluation and supervision of medicines in the EU [EMA]










5.4 TRAITEMENTS - ECONOMIE



Swayed by discounts, NICE finally backs Roche's Perjeta for postsurgery breast cancer [Fierce Pharma]











Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib [NICE]










Alunbrig recommended by NICE for non-small-cell lung cancer [Pharma Times]











5.5.14 ASCO (VESSIE)



Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients [Reuters]











5.5.19 ASCO (REIN)



Hunt for immunotherapy combinations turns up success in kidney cancer [Biopharma Dive]











KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC) [Merck]











Immunotherapies could change kidney cancer care, studies suggest [CNN]











Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma [NEJM]










Merck, Pfizer drug combo extends kidney cancer survival: study [Reuters]











5.5.3 ASCO (PROSTATE)



With safety data, Bayer could challenge Erleada, Xtandi in prostate cancer: analyst [Fierce Pharma]










New prostate cancer data puts Bayer drug in line with Pfizer, J&J rivals [Biopharma Dive]











New Clinical Data Analysis Shows Survival Benefit Three Years after Treatment with Sipuleucel-T [AP]











6. LUTTE CONTRE LES CANCERS



Two Health Consortia to Develop a Detailed Feasibility Proposal for Europe’s Next €1-billion Science Projects [ESMO]











6.11 PATIENTS



'Not Letting It Define Us' — Walking The Runway With Metastatic Breast Cancer [NPR]











Patients and Physicians in the Era of Modern Cancer Care [JAMA]










6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Ranjana Srivastava: When cancer patients want quackery [Respectful Insolence]











6.6 PUBLICATIONS



Rare trial of open peer review allays common concerns [Nature]











6.7.1 IA/BIOINFORMATIQUE



Artificial intelligence can predict survival of ovarian cancer patients [Imperial College London]











AAAS: Machine learning 'causing science crisis' [BBC News]